Skip to content

Lung squamous cell carcinoma — staging

TL;DR — LUSC uses the same TNM system as other lung carcinomas; histology does not alter the anatomic category. The ninth edition became effective in 2025 and retains eighth-edition T categories while splitting N2 into single-station N2a and multistation N2b, and M1c into multiple metastases within one organ system (M1c1) versus multiple organ systems (M1c2) (Van Schil 2024, PMID 38070600; Huang 2024, PMID 37866624; Fong 2024, PMID 38320664). LUSC nevertheless creates staging pitfalls: central tumors may be small in radial dimension yet invade a main bronchus, cause obstructive atelectasis/pneumonitis, cross the carina, or generate separate ipsilateral nodules; each changes T category independently of diameter. PET-CT improves whole-body and mediastinal assessment but abnormal nodes generally require tissue confirmation when management would change; EBUS/EUS provide minimally invasive sampling, with surgical staging reserved for selected discordant or high-risk cases (De Leyn 2014, PMID 24578407; Vilmann 2015, PMID 26030890). The actionable output is not TNM alone: resectability, cardiopulmonary fitness, molecular/PD-L1 status, and multidisciplinary judgment determine treatment within an anatomic stage (Daly 2022, PMID 34936470).

Edition and evidence base

The ninth-edition IASLC database was designed from cases diagnosed in 2011–2019 and sought broader geographic, treatment, and data-source representation than earlier editions (Asamura 2023, PMID 36773775). TNM remains a prognostic anatomic classification, not a treatment algorithm or biological taxonomy.

Ninth-edition component Change from eighth edition Rationale/source
T Size and invasion categories retained Existing cut points remained prognostically useful; Van Schil 2024, PMID 38070600
N N2 → N2a (single ipsilateral mediastinal/subcarinal station) and N2b (multiple stations) Number of involved mediastinal stations adds prognostic discrimination; Huang 2024, PMID 37866624
M M1c → M1c1 (multiple extrathoracic metastases in one organ system) and M1c2 (multiple organ systems) Organ distribution separates prognosis; Fong 2024, PMID 38320664
Stage groups Regrouped to incorporate N2a/N2b and M1c1/M1c2 Derived from survival analyses; Rami-Porta 2024, PMID 38447919
Histologic descriptor Spread through air spaces (STAS) recorded Prognostic descriptor, not a T-category modifier; Travis 2024, PMID 38508515
Residual tumor R classification refined Separates completeness of resection from baseline TNM; Detterbeck 2024, PMID 38569931

An external 6,649-patient surgical cohort found significant overall- and recurrence-free-survival separation between N0, N1, N2a, and N2b, supporting the N2 split (Kim 2024, PMID 38614456). A second 4,029-case cohort found improved discrimination versus the eighth edition, though retrospective surgical series underrepresent unresectable and metastatic disease (Son 2024, PMID 39604857).

T category: size and local extent

The table is a working research summary. Formal staging should use the complete current IASLC/UICC/AJCC specification because rare combinations and measurement rules are not captured here (Van Schil 2024, PMID 38070600; Kuhtić 2025, PMID 40218258).

Category Core descriptor LUSC-relevant examples
Tis Carcinoma in situ Flat endobronchial squamous CIS without stromal invasion
T1mi Minimally invasive adenocarcinoma construct Not a usual LUSC category
T1a Invasive tumor ≤1 cm Small peripheral or endobronchial invasive focus
T1b >1 to ≤2 cm Size measured by greatest invasive dimension
T1c >2 to ≤3 cm No qualifying higher local invasion
T2a >3 to ≤4 cm, or qualifying T2 feature Main-bronchus involvement without carina; visceral pleura; obstructive atelectasis/pneumonitis extending to hilum
T2b >4 to ≤5 cm Same non-size T2 rules apply
T3 >5 to ≤7 cm or selected local invasion; separate nodule in same lobe Chest wall/parietal pleura, phrenic nerve, parietal pericardium; same-lobe satellite
T4 >7 cm or specified critical invasion; separate nodule in different ipsilateral lobe Mediastinum, diaphragm, heart/great vessels, recurrent laryngeal nerve, trachea/carina, esophagus, vertebral body

Central LUSC makes non-size descriptors especially important. A 2-cm tumor involving the main bronchus without the carina is not staged like an otherwise uncomplicated 2-cm peripheral nodule; airway anatomy can set a T2 category (Van Schil 2024, PMID 38070600).

Obstructive atelectasis or pneumonitis is a staging descriptor, but infection severity, oxygen requirement, or need for bronchoscopic debulking does not independently change TNM. Clinical urgency and anatomic stage are related but distinct.

Separate tumor nodules require careful distinction from synchronous primary cancers. A nodule in the same lobe is T3; a different ipsilateral lobe is T4; contralateral pulmonary nodule is M1a—if clonally related metastasis rather than an independent primary. Airway field carcinogenesis makes this distinction unusually relevant in smokers with squamous lesions (Pipinikas 2014, PMID 24550057).

N category: anatomic map plus station count

Category Definition Ninth-edition nuance
N0 No regional nodal metastasis Imaging N0 is not pathologic N0
N1 Ipsilateral peribronchial and/or hilar/intrapulmonary nodes Includes direct extension into an N1 node
N2a Single ipsilateral mediastinal and/or subcarinal station Newly separated from multistation N2
N2b Multiple ipsilateral mediastinal/subcarinal stations Worse prognosis than N2a in derivation/validation
N3 Contralateral mediastinal or hilar, or scalene/supraclavicular nodes Usually changes curative surgical strategy

The ninth edition counts stations, not simply nodes: three positive nodes within one mediastinal station remain N2a, whereas one positive node in each of two mediastinal stations is N2b (Huang 2024, PMID 37866624).

Nodal map accuracy matters for central LUSC because drainage can involve hilar and mediastinal stations even when a parenchymal mass is not large. Occult nodal metastasis occurs in clinically N0/N1 NSCLC and worsens survival, so PET-negative status is not equivalent to microscopic exclusion (Veeramachaneni 2008, PMID 18249130; Beyaz 2020, PMID 33189983).

M category

Category Definition Typical example
M0 No distant metastasis Curative-intent pathways remain possible depending on T/N and fitness
M1a Intrathoracic metastatic pattern Contralateral lung nodule; pleural/pericardial nodules; malignant pleural/pericardial effusion
M1b Single extrathoracic metastasis One brain, adrenal, bone, liver, or other distant lesion
M1c1 Multiple extrathoracic metastases in one organ system Multiple bone metastases only
M1c2 Multiple extrathoracic metastases in multiple organ systems Bone plus liver, or brain plus adrenal

The M1c subdivision captures disease distribution but not total volume, lesion size, pace, or molecular biology. “Oligometastatic” is a treatment-oriented construct overlapping mainly with M1b and selected limited M1c disease, not a separate TNM category. A consensus definition permits up to five metastases in up to three organs when all sites can be treated radically, but imaging and multidisciplinary feasibility are integral (Dingemans 2019, PMID 31398540).

Pleural fluid must be interpreted carefully: a clearly malignant effusion is M1a, while repeatedly cytology-negative, non-bloody fluid judged unrelated to tumor may be excluded under formal rules. Pleural lavage cytology carries prognostic information even when it does not automatically map to the same category as overt malignant effusion (Nakao 2015, PMID 25762707).

Clinical versus pathologic stage

Prefix/context Evidence basis Use
cTNM Imaging, examination, bronchoscopy, needle biopsy Treatment planning before definitive therapy
pTNM Resection and systematic pathologic evaluation Most complete local/nodal definition after surgery
ycTNM Clinical assessment after systemic/radiation treatment Response-era treatment planning
ypTNM Pathology after neoadjuvant therapy Residual anatomic disease; does not erase baseline stage
rTNM Recurrence Describes recurrent extent

Clinical and pathologic stages answer different questions and should not be silently mixed in outcomes tables. Downstaging after neoadjuvant therapy is prognostic, but a ypT0N0 specimen does not mean the original cancer never existed.

Staging workup

Modality/procedure Primary question Major limitation
Contrast CT chest/upper abdomen Tumor anatomy, nodes, liver/adrenals, pleura Size criteria miss microscopic nodal disease
FDG PET-CT Metabolically active nodes and distant sites Inflammation/infection causes false positives; small/low-uptake lesions cause false negatives
Brain MRI with contrast Intracranial metastasis Yield varies by stage and symptoms; access differs
Bronchoscopy Endobronchial extent, carina, tissue Does not assess all extrinsic invasion
EBUS-TBNA Mediastinal/hilar nodal tissue Operator access, sampling adequacy, false negatives
EUS-FNA/EUS-B Posterior/inferior mediastinal stations, left adrenal Complementary station access
Mediastinoscopy/VAMLA Surgical mediastinal confirmation Invasive; targeted use after endosonography
Thoracoscopy/pleural sampling Pleural nodules or unexplained effusion Procedural risk; negative cytology alone may be insufficient

PET-CT is a map for biopsy, not a replacement for it when nodal status determines surgery versus chemoradiation. Revised ESTS guidance recommends invasive confirmation of PET-positive mediastinal nodes and systematic endosonographic staging in appropriate central/high-risk tumors (De Leyn 2014, PMID 24578407).

Combined EBUS and esophageal endosonography expands accessible stations and can provide diagnosis plus staging in one pathway (Vilmann 2015, PMID 26030890). In a 774-patient multicenter EBUS-TBNA cohort, NSCLC diagnostic accuracy was 91% (95% CI 89–93), but this performance does not imply 91% sensitivity for every nodal station (Navani 2012, PMID 22505743).

LUSC-specific staging pitfalls

Pitfall Consequence Resolution
Post-obstructive pneumonia mistaken for tumor Overestimated primary size or invasion Reimage after airway treatment when safe; correlate bronchoscopy
Central tumor underestimated by longest diameter Missed main bronchus/carina descriptor Multiplanar CT + bronchoscopy; Van Schil 2024, PMID 38070600
Inflammatory FDG-avid nodes in smokers/COPD False-positive N2/N3 EBUS/EUS tissue confirmation; De Leyn 2014, PMID 24578407
Necrotic/cavitary primary with low viable fraction Inadequate biopsy or underestimated uptake Target viable wall; coordinate pathology and imaging
Second squamous lesion assumed metastatic Incorrect T3/T4/M1a instead of synchronous primary Compare anatomy, precursor field, interval, and molecular clonality where feasible; Pipinikas 2014, PMID 24550057
Head-and-neck SCC metastasis labeled lung primary Wrong site and stage Clinical history and HPV/molecular comparison; Schulte 2020, PMID 32350806

Histology-specific prognostic nuance

TNM is the strongest common anatomic frame, but equal TNM does not guarantee equal prognosis. Peripheral versus central resected LUSC differed in tumor size and nodal frequency, yet location itself was not independently prognostic in a 268-patient series (Lin 2019, PMID 30456676).

After definitive chemoradiation, adenocarcinoma and squamous NSCLC can show different failure patterns; one analysis reported histology-associated differences relevant to radiation surveillance, but retrospective treatment-era effects limit generalization (Ito 2020, PMID 31667664; McAleese 2019, PMID 31351746).

In stage-I LUSC, lymphatic invasion predicted worse outcome in a surgical cohort, a feature not represented in T size alone (Tsutani 2015, PMID 25248914). STAS is now a recorded descriptor based on analysis of 4,061 pathologic stage-I NSCLCs, but its biology and measurement are more established in adenocarcinoma than LUSC and it does not alter the T category (Travis 2024, PMID 38508515).

Stage is not resectability

Resectability depends on technical anatomy, nodal bulk/stations, ability to achieve complete resection, and cardiopulmonary fitness. Stage III is particularly heterogeneous; an international survey documented substantial disagreement about resectability, reinforcing multidisciplinary assessment rather than a stage-label shortcut (Houda 2025, PMID 39705827).

Similarly, an early-stage patient with severe COPD may be medically inoperable but still eligible for curative stereotactic radiotherapy, whereas selected stage IIIA/N2a disease may enter multimodality pathways. Treatment synthesis is covered in early-stage and perioperative therapy and systemic therapy.

Open questions

  • Does the N2a/N2b split improve treatment selection, or only prognostic granularity, in prospective stage-III trials (Huang 2024, PMID 37866624; Kim 2024, PMID 38614456)?
  • Can ctDNA detect occult nodal or distant disease beyond PET-CT without causing false-positive stage migration?
  • How should multiple airway-field LUSCs be classified when morphology is identical but clonality is uncertain (Pipinikas 2014, PMID 24550057)?
  • Do central location, cavitation, or lymphatic invasion add enough validated prognostic information to supplement TNM in LUSC (Lin 2019, PMID 30456676; Tsutani 2015, PMID 25248914)?
  • Will the ninth edition remain calibrated across regions and treatment eras underrepresented in its 2011–2019 database (Asamura 2023, PMID 36773775)?

References

  1. Asamura H, Nishimura KK, Giroux DJ, Chansky K, Hoering A, Rusch V, et al. IASLC Lung Cancer Staging Project: The New Database to Inform Revisions in the Ninth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2023;18(5):564-575. PMID 36773775
  2. Van Schil PE, Asamura H, Nishimura KK, Rami-Porta R, Kim YT, Bertoglio P, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revisions of the T-Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2024;19(5):749-765. PMID 38070600
  3. Huang J, Osarogiagbon RU, Giroux DJ, Nishimura KK, Bille A, Cardillo G, et al. The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the N Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2024;19(5):766-785. PMID 37866624
  4. Fong KM, Rosenthal A, Giroux DJ, Nishimura KK, Erasmus J, Lievens Y, et al. The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2024;19(5):786-802. PMID 38320664
  5. Rami-Porta R, Nishimura KK, Giroux DJ, Detterbeck F, Cardillo G, Edwards JG, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2024;19(7):1007-1027. PMID 38447919
  6. Travis WD, Eisele M, Nishimura KK, Aly RG, Bertoglio P, Chou TY, et al. The International Association for the Study of Lung Cancer (IASLC) Staging Project for Lung Cancer: Recommendation to Introduce Spread Through Air Spaces as a Histologic Descriptor in the Ninth Edition of the TNM Classification of Lung Cancer. Analysis of 4061 Pathologic Stage I NSCLC. J Thorac Oncol. 2024;19(7):1028-1051. PMID 38508515
  7. Detterbeck FC, Ostrowski M, Hoffmann H, Rami-Porta R, Osarogiagbon RU, Donnington J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the Classification of Residual Tumor After Resection for the Forthcoming (Ninth) Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2024;19(7):1052-1072. PMID 38569931
  8. Kim IH, Lee GD, Choi S, Kim HR, Kim YH, Kim DK, et al. Validation Study for the N Descriptor of the Newly Proposed Ninth Edition of the TNM Staging System Proposed by the International Association for the Study of Lung Cancer. J Thorac Oncol. 2024;19(8):1218-1227. PMID 38614456
  9. Son JW, Lee J, Jeon JH, Cho S, Jung W, Shih BC, et al. Validation of IASLC 9th edition TNM classification for lung cancer: focus on N descriptor. BMC Cancer. 2024;24(1):1460. PMID 39604857
  10. Kuhtić I, Mandić Paulić T, Kovačević L, Badovinac S, Jakopović M, Dobrenić M, et al. Clinical TNM Lung Cancer Staging: A Diagnostic Algorithm with a Pictorial Review. Diagnostics (Basel). 2025;15(7). PMID 40218258
  11. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39-51. PMID 26762738
  12. Pipinikas CP, Kiropoulos TS, Teixeira VH, Brown JM, Varanou A, Falzon M, et al. Cell migration leads to spatially distinct but clonally related airway cancer precursors. Thorax. 2014;69(6):548-57. PMID 24550057
  13. De Leyn P, Dooms C, Kuzdzal J, Lardinois D, Passlick B, Rami-Porta R, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014;45(5):787-98. PMID 24578407
  14. Vilmann P, Clementsen PF, Colella S, Siemsen M, De Leyn P, Dumonceau JM, et al. Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). Endoscopy. 2015;47(6):545-59. PMID 26030890
  15. Navani N, Brown JM, Nankivell M, Woolhouse I, Harrison RN, Jeebun V, et al. Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients. Am J Respir Crit Care Med. 2012;185(12):1316-22. PMID 22505743
  16. Veeramachaneni NK, Battafarano RJ, Meyers BF, Zoole JB, Patterson GA. Risk factors for occult nodal metastasis in clinical T1N0 lung cancer: a negative impact on survival. Eur J Cardiothorac Surg. 2008;33(3):466-9. PMID 18249130
  17. Beyaz F, Verhoeven RLJ, Schuurbiers OCJ, Verhagen AFTM, van der Heijden EHFM. Occult lymph node metastases in clinical N0/N1 NSCLC; A single center in-depth analysis. Lung Cancer. 2020;150:186-194. PMID 33189983
  18. Dingemans AC, Hendriks LEL, Berghmans T, Levy A, Hasan B, Faivre-Finn C, et al. Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report. J Thorac Oncol. 2019;14(12):2109-2119. PMID 31398540
  19. Nakao M, Hoshi R, Ishikawa Y, Matsuura Y, Uehara H, Mun M, et al. Prognosis of non-small-cell lung cancer patients with positive pleural lavage cytology. Interact Cardiovasc Thorac Surg. 2015;20(6):777-82. PMID 25762707
  20. Schulte JJ, Steinmetz J, Furtado LV, Husain AN, Lingen MW, Cipriani NA. Metastatic HPV-Associated Oropharyngeal Versus Primary Pulmonary Squamous Cell Carcinoma: is p16 Immunostain Useful? Head Neck Pathol. 2020;14(4):966-973. PMID 32350806
  21. Lin MW, Huang YL, Yang CY, Kuo SW, Wu CT, Chang YL. The Differences in Clinicopathologic and Prognostic Characteristics Between Surgically Resected Peripheral and Central Lung Squamous Cell Carcinoma. Ann Surg Oncol. 2019;26(1):217-229. PMID 30456676
  22. Ito H, Matsuo Y, Ohtsu S, Nishimura T, Terada Y, Sakamoto T, et al. Impact of histology on patterns of failure and clinical outcomes in patients treated with definitive chemoradiotherapy for locally advanced non-small cell lung cancer. Int J Clin Oncol. 2020;25(2):274-281. PMID 31667664
  23. McAleese J, Taylor A, Walls GM, Hanna GG. Differential Relapse Patterns for Non-small Cell Lung Cancer Subtypes Adenocarcinoma and Squamous Cell Carcinoma: Implications for Radiation Oncology. Clin Oncol (R Coll Radiol). 2019;31(10):711-719. PMID 31351746
  24. Tsutani Y, Miyata Y, Mimura T, Kushitani K, Takeshima Y, Yoshimura M, et al. Prognostic impact of lymphatic invasion for pathological stage I squamous cell carcinoma of the lung. Gen Thorac Cardiovasc Surg. 2015;63(3):153-8. PMID 25248914
  25. Daly ME, Singh N, Ismaila N, Antonoff MB, Arenberg DA, Bradley J, et al. Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline. J Clin Oncol. 2022;40(12):1356-1384. PMID 34936470
  26. Houda I, Bahce I, Dickhoff C, Kroese TE, Kroeze SGC, Mariolo AV, et al. An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer. Lung Cancer. 2025;199:108061. PMID 39705827